Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 457

Similar articles for PubMed (Select 16160618)

1.

Drug-induced agranulocytosis: impact of different fcgamma receptor polymorphisms?

Mosyagin I, Cascorbi I, Schaub R, Krüger T, Dettling M.

J Clin Psychopharmacol. 2005 Oct;25(5):435-40.

PMID:
16160618
2.

Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6.

Dettling M, Sachse C, Müller-Oerlinghausen B, Roots I, Brockmöller J, Rolfs A, Cascorbi I.

Pharmacopsychiatry. 2000 Nov;33(6):218-20.

PMID:
11147929
3.

Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis.

Mosyagin I, Dettling M, Roots I, Mueller-Oerlinghausen B, Cascorbi I.

J Clin Psychopharmacol. 2004 Dec;24(6):613-7.

PMID:
15538122
4.

Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry.

Dettling M, Schaub RT, Mueller-Oerlinghausen B, Roots I, Cascorbi I.

Pharmacogenetics. 2001 Mar;11(2):135-41.

PMID:
11266078
5.

Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis.

Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA, Zou W, Whalen H, Malhotra AK, Lencz T, Gerson SL, Kane JM, Reed CR.

J Clin Psychiatry. 2011 Apr;72(4):458-63. doi: 10.4088/JCP.09m05527yel. Epub 2010 Sep 21.

PMID:
20868635
6.

N-desmethylclozapine, an insensitive marker of clozapine-induced agranulocytosis and granulocytopenia.

Combs MD, Perry PJ, Bever KA.

Pharmacotherapy. 1997 Nov-Dec;17(6):1300-4.

PMID:
9399615
7.

Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens.

Dettling M, Cascorbi I, Opgen-Rhein C, Schaub R.

Pharmacogenomics J. 2007 Oct;7(5):325-32. Epub 2006 Oct 17.

PMID:
17001352
8.

FcgammaRIIa-131R allele and FcgammaRIIIa-176V/V genotype are risk factors for progression of IgA nephropathy.

Tanaka Y, Suzuki Y, Tsuge T, Kanamaru Y, Horikoshi S, Monteiro RC, Tomino Y.

Nephrol Dial Transplant. 2005 Nov;20(11):2439-45.

9.

Clozapine induced agranulocytosis: hypothesis on immune-mediated pathogenesis and the role of haematopoietic growth factors.

Faber HJ, Smit AJ, van de Loosdrecht AA.

Neth J Med. 1999 Aug;55(2):86-7. No abstract available.

PMID:
10474279
10.

Mitchell B. Balter Award. Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia.

Lahdelma L, Ahokas A, Andersson LC, Suvisaari J, Hovatta I, Huttunen MO, Koskimies S.

J Clin Psychopharmacol. 2001 Feb;21(1):4-7.

PMID:
11199946
11.

[Clozapine-induced agranulocytosis: genetic risk factors and an immunologic explanatory model].

Güzelcan Y, Scholte WF.

Tijdschr Psychiatr. 2006;48(4):295-302. Review. Dutch.

12.

HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients.

Valevski A, Klein T, Gazit E, Meged S, Stein D, Elizur A, Narinsky ER, Kutzuk D, Weizman A.

Eur J Immunogenet. 1998 Feb;25(1):11-3.

PMID:
9587740
13.

Testing the hypothesis that selenium deficiency is a risk factor for clozapine-induced agranulocytosis in rats.

Ip J, Uetrecht JP.

Chem Res Toxicol. 2008 Apr;21(4):874-8. doi: 10.1021/tx7004037. Epub 2008 Apr 2.

PMID:
18380444
14.

Clozapine treatment in Australia: a review of haematological monitoring.

Copolov DL, Bell WR, Benson WJ, Keks NA, Strazzeri DC, Johnson GF.

Med J Aust. 1998 May 18;168(10):495-7.

PMID:
9631674
15.

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.

Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA.

N Engl J Med. 1993 Jul 15;329(3):162-7.

16.

Human leukocyte antigen typing, response to neuroleptics, and clozapine-induced agranulocytosis in jewish Israeli schizophrenic patients.

Meged S, Stein D, Sitrota P, Melamed Y, Elizur A, Shmuelian I, Gazit E.

Int Clin Psychopharmacol. 1999 Sep;14(5):305-12.

PMID:
10529073
17.

Clozapine rechallenge after excluding the high-risk clozapine-induced agranulocytosis genotype of HLA-DQB1 6672G>C.

McKnight C, Guirgis H, Votolato N.

Am J Psychiatry. 2011 Oct;168(10):1120. doi: 10.1176/appi.ajp.2011.11020202. No abstract available.

PMID:
21969051
18.

Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis.

Rudolf J, Grond M, Neveling M, Heiss WD.

J Neural Transm. 1997;104(11-12):1305-11.

PMID:
9503276
19.

Long-term patient monitoring for clozapine-induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS?

Kang BJ, Cho MJ, Oh JT, Lee Y, Chae BJ, Ko J.

Hum Psychopharmacol. 2006 Aug;21(6):387-91.

PMID:
16933201
20.

Clozapine-induced agranulocytosis: a case report. Immunopathophysiological considerations.

van de Loosdrecht AA, Faber HJ, Hordijk P, Uges DR, Smit A.

Neth J Med. 1998 Jan;52(1):26-9.

PMID:
9573739
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk